Dickinson Andrew D

SEC source: 0001310204-26-000029 · wk-form4_1789590643.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 164,096

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-26-000027 · wk-form4_1789165843.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,054

Underlying: Common Stock · 2,797 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-26-000027 · wk-form4_1789165843.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,096

SEC source: 0001310204-26-000027 · wk-form4_1789165843.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,443

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001310204-26-000024 · wk-form4_1787094366.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 165,646

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-26-000022 · wk-form4_1784239680.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,646

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · price: Sale prices for the transactions reported range from $129.45 to $130.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001310204-26-000020 · wk-form4_1781646803.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,646

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-26-000018 · wk-form4_1781217163.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,851

Underlying: Common Stock · 2,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-26-000018 · wk-form4_1781217163.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,646

SEC source: 0001310204-26-000018 · wk-form4_1781217163.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001310204-26-000016 · wk-form4_1779141028.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,191

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-26-000014 · wk-form4_1776379311.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 176,191

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-26-000012 · wk-form4_1773785637.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 179,191

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-26-000010 · wk-form4_1773348337.xml · derivative · entry 5

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,880

Underlying: Common Stock · 35,880 shares

Expires 2036-03-10

F3 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-26-000010 · wk-form4_1773348337.xml · derivative · entry 4

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,647

Underlying: Common Stock · 9,590 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-26-000010 · wk-form4_1773348337.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,057

Underlying: Common Stock · 6,469 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-26-000010 · wk-form4_1773348337.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,191

SEC source: 0001310204-26-000010 · wk-form4_1773348337.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001310204-26-000008 · wk-form4_1772488649.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,869

F1 · acquired: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001310204-26-000006 · wk-form4_1771452697.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 167,779

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · balance_after: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

SEC source: 0001310204-26-000004 · wk-form4_1770335396.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,568

SEC source: 0001310204-26-000004 · wk-form4_1770335396.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,370

F1 · acquired: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2023 and March 10, 2024. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares certified for grants made March 10, 2024 will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001310204-26-000002 · wk-form4_1768605499.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,503

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-25-000021 · wk-form4_1765927916.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,503

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-25-000019 · wk-form4_1765503597.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,526

Underlying: Common Stock · 3,693 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-25-000019 · wk-form4_1765503597.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,503

SEC source: 0001310204-25-000019 · wk-form4_1765503597.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001310204-25-000017 · wk-form4_1763510402.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 154,555

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-25-000014 · wk-form4_1760664900.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 157,055

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-25-000011 · wk-form4_1758057124.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,555

F1 · kind: The transaction reported in the this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001310204-25-000007 · wk-form4_1757629717.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,219

Underlying: Common Stock · 3,696 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-25-000007 · wk-form4_1757629717.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,055

SEC source: 0001310204-25-000007 · wk-form4_1757629717.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,806

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001310204-25-000005 · wk-form4_1755560041.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 160,110

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001127602-25-019286 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 162,610

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001127602-25-017692 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 165,110

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001127602-25-017331 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,915

Underlying: Common Stock · 3,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-017331 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,610

SEC source: 0001127602-25-017331 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,368

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-25-014718 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 165,674

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001127602-25-012101 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,174

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001127602-25-009796 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 170,674

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001127602-25-009283 · form4.xml · derivative · entry 11

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,609

Underlying: Common Stock · 11,090 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F4 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F6 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F6 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-009283 · form4.xml · derivative · entry 10

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,020

Underlying: Common Stock · 49,020 shares

Expires 2035-03-10

F5 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-009283 · form4.xml · derivative · entry 9

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,519

Underlying: Common Stock · 7,968 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F4 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F6 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F6 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-009283 · form4.xml · derivative · entry 8

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,013 shares

Expires 2031-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F5 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-009283 · form4.xml · derivative · entry 7

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,013

Underlying: Common Stock · 4,916 shares

Expires 2031-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F5 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-009283 · form4.xml · nonDerivative · entry 6

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,174

SEC source: 0001127602-25-009283 · form4.xml · nonDerivative · entry 5

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-25-009283 · form4.xml · nonDerivative · entry 4

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 169,061

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F3 · price: Sale prices reported for the transactions reported here range from $118.00 to $118.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.